NeoPhore Ltd

📍 Cambridge, United Kingdom🗓 Founded 2017👥 22 employees💰 Last funded Dec 2023
Biotechnology Research🌐 neophore.com
Website LinkedIn
NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund.
2
Total investors
1
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United Kingdom
1
Italy
1
Frequently asked questions
Who invested in NeoPhore Ltd?
NeoPhore Ltd has 2 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did NeoPhore Ltd last raise funding?
The most recent investment in NeoPhore Ltd recorded on gritt.io was in December 2023.
When was NeoPhore Ltd founded?
NeoPhore Ltd was founded in 2017.
What industry is NeoPhore Ltd in?
NeoPhore Ltd operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is NeoPhore Ltd based?
NeoPhore Ltd is headquartered in Cambridge, United Kingdom.